A robust reprogramming strategy for generating hepatocyte-like cells usable in pharmaco-toxicological studies

Area of Science:

• Hepatology
• Stem Cell Biology
• Toxicology

Background:

• Established liver cell lines like HepG2 have limitations for high-throughput drug testing due to neoplastic transformation and limited hepatic phenotype.
• Primary hepatocytes and pluripotent stem cell-derived hepatocytes are costly and difficult to implement in large-scale screening.
• There is a need for non-transformed, well-differentiated, scalable, and patient-specific liver cell models.

Purpose of the Study:

• To develop a novel and robust method for generating patient-specific induced hepatocyte-like cells from fibroblasts.
• To create a scalable and reliable cell model for high-throughput pharmaco-toxicological testing.
• To establish a system for studying inherited liver diseases using patient-derived cells.

Main Methods:

• Direct reprogramming of human fibroblasts using a doxycycline-inducible polycistronic vector expressing HNF4A, HNF1A, and FOXA3.
• Pre-transduction of fibroblasts with human telomerase reverse transcriptase (hTERT) to ensure long-term proliferation without senescence.
• Simple induction of hepatocyte differentiation using doxycycline in standard cell culture media.

Main Results:

• Generated clonal, non-transformed hepatocyte-like cells from fibroblasts that maintain proliferative capacity up to 110 population doublings.
• Achieved hepatocyte differentiation within 10 days using simple, inexpensive media and standard 2D culture conditions.
• Demonstrated that reprogrammed hepatocytes outperform HepG2 cells in toxicological screening and can recapitulate disease phenotypes, such as alpha-1 antitrypsin deficiency.

Conclusions:

• The developed strategy provides an unlimited source of functional, non-transformed induced hepatocyte-like cells suitable for high-throughput drug screening.
• This method enables the generation of patient-specific liver cells that retain disease characteristics, facilitating the study of various hepatic dysfunctions.
• The induced hepatocyte-like cells represent a significant advancement for personalized medicine and drug development in liver diseases.